MAXIMISE (Managing AXlaI Manifestations in Psorlatic Arthritis with SEcukinumab), a randomized, doubled-blind, placebo-controlled, multi center, 52-week study to assess the efficacy ans safety of secukinumab 150 mg or 300 mg s.c. in patients with active psoriatic arthritis and axial skeleton involvement who have inadequate response to non-steroidal anti-infiammatory drugs (NSAIDs)

1. Home
2. Research
3. Projects
4. MAXIMISE (Managing AXlaI Manifestations in Psorlatic Arthritis with SEcukinumab), a randomized, doubled-blind, placebo-controlled, multi center, 52-week study to assess the efficacy ans safety of secukinumab 150 mg or 300 mg s.c. in patients with active psoriatic arthritis and axial skeleton involvement who have inadequate response to non-steroidal anti-infiammatory drugs (NSAIDs)